

Ref: FOI/GS/ID 5949

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

13 February 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Crohn's Disease and Ulcerative Colitis.

You asked:

Could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Crohn's Disease, for each of the following treatments:

*Adalimumab [Amgevita]
Adalimumab [Hulio]
Adalimumab [Humira]
Adalimumab [Hyrimoz]
Adalimumab [Imraldi]
Infliximab [Flixabi]
Infliximab [Inflectra]
Infliximab [Remicade]
Infliximab [Remsima]
Ustekinumab [Stelara]
Vedolizumab [Entyvio]*

Also, could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Ulcerative Colitis, for each of the following treatments:

*Adalimumab [Amgevita]
Adalimumab [Hulio]
Adalimumab [Humira]
Adalimumab [Hyrimoz]
Adalimumab [Imraldi]*

Golimumab [Simponi]
 Infliximab [Flixabi]
 Infliximab [Inflectra]
 Infliximab [Remicade]
 Infliximab [Remsima]
 Tofacitinib [Xeljanz]
 Ustekinumab [Stelara]
 Vedolizumab [Entyvio]

If you are unable to answer my questions with breakdown by specified conditions then please provide me with the numbers of patients treated in the last 3 months (October to December 2019 inclusive if possible) with the above drugs, regardless of disease/indication.

Trust response:

Figures For 17/10/2019 to 17/01/2020	
Cohn's	
Treatment	Number of patients treated
Adalimumab [Amgevita]	1
Adalimumab [Hulio]	0
Adalimumab [Humira]	15
Adalimumab [Hyrimoz]	0
Adalimumab [Imraldi]	108
Infliximab [Flixabi]	0
Infliximab [Inflectra]	0
Infliximab [Remicade]	0
Infliximab [Remsima]	39
Ustekinumab [Stelara]	33
Vedolizumab [Entyvio]	12
Ulcerative Colitis	
Treatment	Number of patients treated
Adalimumab [Amgevita]	0
Adalimumab [Hulio]	0
Adalimumab [Humira]	2
Adalimumab [Hyrimoz]	0
Adalimumab [Imraldi]	30
Golimumab [Simponi]	1
Infliximab [Flixabi]	0
Infliximab [Inflectra]	0
Infliximab [Remicade]	0
Infliximab [Remsima]	8
Tofacitinib [Xeljanz]	3
Ustekinumab [Stelara]	1
Vedolizumab [Entyvio]	15